- Ventripoint Diagnostics (TSXV:VPT) achieved another milestone in its work to provide accurate volumetric cardiac measurements equivalent to MRI
- The artificial intelligence (AI) healthcare stock is updating the submission of its next-generation software, VMS+ 4.0, to the U.S. Food and Drug Administration (FDA) for clearance
- Ventripoint updated its submission of VMS+ 4.0 for FDA clearance on January 17, 2025, to meet requirements for significant software and hardware updates and diagnostic advances
- Ventripoint Diagnostics stock (TSXV:VPT) last traded at $0.10
Ventripoint Diagnostics (TSXV:VPT) achieved another milestone in its work to provide accurate volumetric cardiac measurements equivalent to magnetic resonance imaging (MRI).
The artificial intelligence (AI) healthcare stock is updating the submission of its next-generation software, VMS+ 4.0, to the U.S. Food and Drug Administration (FDA) for clearance.
This update addresses critical questions regarding cybersecurity and AI.
The latest advancement in Ventripoint’s proprietary technology, VMS+ 4.0, introduces two major enhancements aimed at improving clinical workflows:
- AI-assisted echocardiogram image analysis
- Simplified sensors pairing workflow
These improvements build upon the benefits of VMS+ 3.0, which include:
- Full-scope use allowing all patient groups to be easily scanned and assessed.
- Magnet-free sensors expanding the range of patients who can benefit.
- Vendor-neutral interfacing with any ultrasound machine.
“Ventripoint is a pioneer in the application of AI to echocardiography, and VMS+ 4.0 is the result of over two years of research and development,” Ventripoint’s president and CEO, Hugh MacNaught said in a news release. “We are grateful for the collaboration by the Avania team to support this update to our submission. Upon FDA clearance, we look forward to offering U.S. hospitals one of the simplest, most effective, non-invasive heart-imaging tools available.”
“Avania is proud to support Ventripoint on this important innovation,” Joel Ironstone, VP of regulatory & advisory services for Avania, added. “As a long-term partner, we have been continually impressed with Ventripoint’s progress and the continual improvements they have made to their products. We excitedly look forward to working with them on their next innovation.”
Last week, Ventripoint updated its submission of VMS+ 4.0 for FDA clearance to meet requirements for significant software and hardware updates and diagnostic advances. VMS+ 4.0 has already secured regulatory clearance in other key markets such as the E.U., U.K., and Canada, making this latest version available to the global community. Earlier versions of Ventripoint’s scanning technology received FDA, Health Canada, and E.U. regulatory approvals and are being used by leading hospitals in the U.S., E.U., U.K., and Canada.
Ventripoint is a medical device company that applies AI technology to echocardiography.
Ventripoint Diagnostics stock (TSXV:VPT) last traded at $0.10.
Join the discussion: Find out what everybody’s saying about this AI healthcare stock on the Ventripoint Diagnostics Ltd. Bullboard and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top image: Ventripoint Diagnostics.)